A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
0439-24
Phase 1 other active
Quick answer
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma for Melanoma is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Melanoma
- Phase
- Phase 1
- Modality
- other
- Status
- active